Drugs / TQB2223
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06649656 | Nov 2024 → Nov 2026 expected | high grade malignant neoplasm | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06320080 | May 2024 → Nov 2025 | hepatocellular carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05894421 | Jun 2023 → Jan 2025 | cancer of unknown primary site | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Results 正大天晴7大创新药亮相ASH 2024，展现血液病领域突破性进展 cttq.com ↗
TQB3473可通过抑制SYK的磷酸化水平，提升ITP患者的血小板水平。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 正大天晴7大创新药亮相ASH 2024，展现血液病领域突破性进展 cttq.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB2223 | “TQB2252 injection is a compound preparation of TQB2223 monoclonal antibody (LAG-3) and penpulimab (PD-1), with a specification of 300mg TQB2223 monoclonal antibody and 100mg...” NCT06649656 ↗ |
| Action | Inhibit | “blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction” NCT05894421 ↗ |
| Modality | Monoclonal antibody | “TQB2223 monoclonal antibody” NCT06649656 ↗ |
| Route | Intravenous | “intravenous injection of TQB2223 injection and Penpulimab injection” NCT05894421 ↗ |